武漢肺炎「救命藥」幕後推手是台灣女性 美無償提供中國卻遭搶先註冊專利
時間：2020-02-06 10:55 新聞引據：、自由亞洲電台、大紀元、新京報、環球生技月刊 撰稿編輯：陳文蔚 被認為是治療
Andy Ye mark this message contains misinformation
｜originally written by Andy Ye
有關「瑞德西韋」英文名字為"Remdesivir", 研發的美國公司為"GILEAD"(資料來源:中央廣播電台https://www.rti.org.tw/news/view/id/2050586);依據上述關鍵字於GILEAD公司網站2020年1月31日發布的新聞中第2段的說明"Remdesivir is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use."最即說明Remdesivir尚未有效（資料來源：https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-the-company-ongoing-response-to-the-2019-new-coronavirus）。
References
中央廣播電台https://www.rti.org.tw/news/view/id/2050586GILEAD公司新聞稿https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-the-company-ongoing-response-to-the-2019-new-coronavirus
https://www.rti.org.tw/news/view/id/2050586);依據上述關鍵字於GILEAD公司網站2020年1月31日發布的新聞中第2段的說明
https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-the-company-ongoing-response-to-the-2019-new-coronavirus）。
武漢肺炎「救命藥」幕後推手是台灣女性 美無償提供中國卻遭搶先註冊專利
時間：2020-02-06 10:55 新聞引據：、自由亞洲電台、大紀元、新京報、環球生技月刊 撰稿編輯：陳文蔚 被認為是治療
Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)
Foster City, Calif., January 31, 2020 — Gilead Sciences today issued the following statement from Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences: "Gilead is working closely with globa
The content above by Cofacts message reporting chatbot and crowd-sourced fact-checking community is licensed under Creative Commons Attribution-ShareAlike 4.0 (CC BY-SA 4.0), the community name and the provenance link for each item shall be fully cited for further reproduction or redistribution.